Explore
Search
Learn
Watch
Portfolio
PHAT
Phathom Pharmaceuticals, Inc.
Healthcare
$5.72
-58%
1Y
$5.72
$5.72
52 weeks
$18.08
PHAT
Phathom Pharmaceuticals, Inc.
$5.72
-57.50%
1Y
Overview
RyuScore
Business
Safety
Valuation
Growth
Market
Financials
Ownership
Latest close: a new 52-week low
Oct 23, 2026
what changed →
Who owns it
opening the register…
More on Phathom Pharmaceuticals, Inc.
PHAT overview
Price, RyuScore, the earnings flow and the five questions at a glance.
PHAT revenue and segments
The quarter as a flow, the full statements, and what the business is made of.
PHAT financial charts
Every reported figure as its own chart, quarterly and trailing twelve months.
Is PHAT a good business?
Margins, returns on capital, cash conversion, R&D and dilution.
Is PHAT financially safe?
Distress and accounting checks, debt cover, drawdowns and factor exposure.
Is PHAT overvalued?
What the price assumes, its own history, peer multiples and a fair-value range.
PHAT growth
Revenue and earnings trajectory, with margins over time.
PHAT price history
Trend and momentum, key levels, total return, seasonality.
PHAT SEC filings and events
The company's own record, every flag beside its market-wide base rate.
Biotechnology
Ranks
#161
of 194 by RyuScore
Compare peers
Random peer
VALN
-1.0%
Valneva SE
DMAC
+1.2%
DiaMedica Therapeutics Inc.
NGNE
-3.3%
Neurogene Inc.
MNPR
-2.8%
Monopar Therapeutics
ARVN
-5.4%
Arvinas
CBIO
-1.7%
Crescent Biopharma